glur

NS-102 is a glutamate receptor and NMDA receptor antagonist that inhibits erythrocyanine (GluK2), which reduces glur6 receptor-mediated currents, and inhibits specific binding to the glur6 receptor.

Aniracetam (Ro 13-5057)(Ro 13-5057), a nootropic and neuroprotective drug, selectively modulates the AMPA receptor and nAChR.

(-)-Camphoric acid (L-Camphoric acid) is a less active enantiomer of Camphoric acid which induces GluR expression.

Xanthurenic Acid (8-Hydroxykynurenic acid), a molecule arising from tryptophan metabolism by transamination of 3-hydroxykynurenine, activates mGlu2/3 Metabotropic glutamate receptors (mGlu2 and mGlu3).

D-Glutamine is the D-type stereoisomer of cell-permeable glutamine, one of the 20 amino acids encoded by the standardized genetic code.

Latrepirdine dihydrochloride (Dimebolin dihydrochloride) is an orally active, and neuroactive antagonist of multiple drug targets, including histamine receptors, GluR, and 5-HT receptors, used as an antihistamine drug.

Transtorine (1,4-DIHYDRO-4-OXOQUINOLINE-2-CARBOXYLIC ACID) is a GluR and NMDA inhibitor.

Dipraglurant (ADX48621) is a negative alteration modulator (NAM) of mGluR5 that inhibits dyskinesia in the LID macaque model.

Foliglurax monohydrochloride Antiparkinsonian effect. is a highly selective and potent, brain-penetrant metabotropic glutamate receptor 4 positive allosteric modulator (mGluR4 PAM) , with an EC50 of 79 nM.

Foliglurax is a highly selective brain-penetrant metabotropic glutamate receptor 4 positive allosteric modulator (mGluR4 PAM) (EC50: 79 nM).

Mavoglurant is a novel, non-competitive mGlu5 receptor antagonist. Mavoglurant (racemate) is the racemate of mavoglurant.

Basimglurant (CTEP Derivative) is a potent, selective and orally available modulator of mGlu5 negative allosteric(Kd of 1.1 nM).

Decoglurant (RO4995819) is a negative allosteric modulator of mGluR2 and mGluR3, developed as an antidepressant.

Auglurant is a novel and selective mGlu5 antagonist (IC50: 11 nM (rat) and an IC50: 14 nM (human)). Auglurant has an acceptable CNS penetration.

mGluR2 modulator6 (Compound 25-a) acts as an mGluR2 modulator demonstrating anticonvulsant activity in the 6Hz epilepsy model, with enhanced effects when used in combination with Levetiracetam. This compound is valuable for epilepsy research.

Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson's disease.

mGluR5 modulator 1 is a compound that acts as a positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5). Its primary application lies in the field of schizophrenia and cognitive impairment research.

mGluR2 antagonist 1 is a potent and selective class of negative allosteric modulator targeting the metabotropic glutamate receptor 2 (mGluR2) with high oral bioavailability. It displays a remarkable affinity for mGluR2, with an IC50 value of 9 nM. Furthermore, it exhibits excellent permeability across the blood-brain barrier, making it a promising candidate for central nervous system-related studies or therapies.

mGluR2 modulator 2 (compound 2) is a potent, selective, and orally bioavailable positive allosteric modulator of mGluR2 with an EC50 value of 0.13 μM [1], and can be used in antipsychotic research.

4 (compound 47) is a highly potent positive allosteric modulator of mGluR2, exhibiting an EC50 value of 0.8 μM, with potential for investigating antipsychotic properties [1].

mGluR2 modulator 1 (compound 95) is a potent, blood-brain-barrier permeable modulator of mGluR2 (metabotropic glutamate receptor-2) with an EC50 of 0.03 μM. mGluR2 modulator 1 can be used in the study of psychiatric disorders.

mGluR3 modulator-1 (1-ethyl-3-(morpholin-4-yl)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile) is a positive allosteric modulator of mGluR3 and can be used in studies about the treatment of Parkinson's disease.

mGluR2 modulator5 (Compound 11) is a selective negative allosteric modulator with oral activity, exhibiting an IC50 of 8.9 nM. Pharmacokinetic studies in rats have demonstrated its effective penetration through the blood-brain barrier. This compound is utilized in research related to cognitive and neurological functions in mood disorders, contributing to the field of neurological diseases.

mGluR2 agonist1 hydrochloride is a potent and selective agonist of the metabotropic glutamate receptor (mGluR2), with an EC50 of 82 nM.